Latest On Eurofins Scientific SE (ERFSF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-07-03 06:01 EST | Dividend | A dividend of $0.5 has been announced on Jun 24, 2024. It will be paid Jul 5, 2024 with an ex-dividend date of Jul 3, 2024. | Neutral |  |
| 2023-07-03 06:01 EST | Dividend | A dividend of $1 has been announced on Jun 20, 2023. It will be paid Jul 6, 2023 with an ex-dividend date of Jul 3, 2023. | Neutral | |
| 2023-04-27 00:48 EST | News | Eurofins Scientific SE. (ERFSF) Q1 2023 - Earnings Call Transcript | N/A | |
| 2023-04-26 12:44 EST | News | Eurofins Scientific reports Q1 results; reaffirms FY23 and FY27 guidance | N/A | |
| 2023-03-31 14:11 EST | News | Introduction To The Testing, Inspection, And Certification (TIC) Market | N/A | |
| 2023-03-04 05:57 EST | News | Eurofins Scientific SE (ERFSF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-02 10:29 EST | News | Eurofins Scientific: Short Term Pain, But Keep Your Eyes On The Long-Term Potential | N/A | |
| 2023-01-14 16:51 EST | News | Eurofins Scientific: A Buy On Any Further Pullback | N/A | |
| 2022-10-19 03:03 EST | News | Eurofins Scientific: Positive Capital Allocation Shifts Reinforce The Bull Case | N/A | |
| 2022-07-05 06:04 EST | Dividend | A dividend of $1 has been announced on Feb 22, 2022. It will be paid Jul 7, 2022 with an ex-dividend date of Jul 5, 2022. | Neutral | |
| 2021-12-10 06:57 EST | News | Eurofins enhances clinical and COVID-19 testing offering in Japan via acquisition of Genetic Lab | N/A | |
| 2021-07-01 06:05 EST | Dividend | A dividend of $0.68 has been announced on Mar 1, 2021. It will be paid Jul 5, 2021 with an ex-dividend date of Jul 1, 2021. | Neutral | |
| 2021-04-29 03:18 EST | News | Eurofins Scientific: COVID-19 Testing To Drive Revenue Growth Further | N/A | |
| 2021-03-04 05:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-03 14:49 EST | News | Eurofins Scientific: Past Performance Is Not Indicative Of Future Results | N/A | |
| 2020-12-02 10:31 EST | News | Eurofins Scientific: This Ten Bagger Just Did A 10:1 Split | N/A | |
| 2020-11-26 23:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 06:38 EST | Stock Split | A stock split has occured on Nov 19, 2020 with a split factor of 10:1. | Neutral | |
| 2020-11-10 01:42 EST | News | (Exclusive) Eurofins Scientific: Capitalizing On COVID-19 Testing, But Preparing For A Post-COVID World | N/A | |
| 2020-11-08 02:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-16 08:33 EST | News | Eurofins to propose a 10:1 stock split | N/A | |
| 2020-09-26 15:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-08 02:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 14:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 16:40 EST | News | Eurofins launches total antibody detection ELISA assays for COVID-19 detection | N/A | |
| 2020-05-27 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 22:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-06 01:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 06:07 EST | Financials | Company financials have been released. | Neutral | |
About Eurofins Scientific SE (ERFSF):
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agroscience, agro testing, assurance, biopharma, clinical diagnostics, consumer product testing, cosmetics and personal care, environment testing, food and feed testing, forensic, genomic, maritime, materials and engineering, technologies, and REACH services. The company serves clients from a range of industries, including the pharmaceutical, food, environmental, and clinical diagnostics sectors. It operates approximately 800 laboratories in 50 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
General
- Name Eurofins Scientific SE
- Symbol ERFSF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 51,516
- Last Split Factor10:1
- Last Split Date2020-11-19
- Fiscal Year EndDecember
- Web URLhttp://www.eurofins.com
View More
Valuation
- Trailing PE 7.96
- Forward PE 24.75
- Price/Sales (Trailing 12 Mt.) 2.79
- Price/Book (Most Recent Quarter) 4.01
- Enterprise Value Revenue 3.8
- Enterprise Value EBITDA 15.7
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 10%
- Return on Assets 7%
- Return on Equity 16%
- Earnings Per Share $12.03
- Revenue Per Share $0
- Gross Profit 1.41 billion
- Quarterly Earnings Growth 30.1%
View More
ESG Rating
Highlights
- Market Capitalization 18.1 billion
- Book Value Per Share $165.51
View More
Share Statistics
- Shares Outstanding 191.04 million
- Shares Float 127.18 million
- % Held by Insiders 3363%
- % Held by Institutions 40.07%
View More
Technicals
- Beta 0.51
- 52 Week High $104.2
- 52 Week Low $44.15
- 50 Day Moving Average 94.98
- 200 Day Moving Average 86.12
View More
Dividends
- Forward Annual Dividend Rate $3.25
- Forward Annual Dividend Yield 0.51%
- Dividend Date N/A
- ExDividend Date 2019-07-03
- Dividend Per Share $2.8
- Dividend Yield 0%
View More
Eurofins Scientific SE (ERFSF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Eurofins Scientific SE (ERFSF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $1.30 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $1.25 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $0.23 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $1.2 billion | $0.22 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $1.2 billion | $0.33 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $1.08 billion | $0.32 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $1.08 billion | $0.11 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $1.02 billion | $0.10 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $1.02 billion | $0.35 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $871.66 million | $0.35 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $871.66 million | $0.23 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $787.24 million | $0.22 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $787.24 million | $0.41 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $698.47 million | $0.40 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $698.47 million | $0.18 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $664.11 million | $0.17 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $664.11 million | $0.29 | $0.00 | |
| 2016-06-30 | 2016-09-30 | $0.31 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $0.15 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $0.15 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.09 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.09 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.06 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $0.06 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.22 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.23 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.07 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.07 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.14 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.14 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.04 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.04 | |||
| 2012-09-30 | 2012-12-31 | $0.17 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.17 | |||
| 2012-03-31 | 2012-06-30 | $0.05 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.05 | |||
| 2011-09-30 | 2011-12-31 | $0.17 | |||
| 2011-06-30 | 2011-09-30 | $0.13 | |||
| 2011-03-31 | 2011-06-30 | $0.09 | |||
| 2010-12-31 | 2011-03-31 | -$0.01 | |||
| 2010-09-30 | 2010-12-31 | $0.08 | |||
| 2010-06-30 | 2010-06-30 | $0.05 | |||
| 2010-03-31 | 2010-03-31 | -$0.03 | |||
| 2009-12-31 | 2009-12-31 | -$0.13 | |||
| 2009-09-30 | 2009-09-30 | $0.05 | |||
| 2009-06-30 | 2009-06-30 | $-0.00 | |||
| 2009-03-31 | 2009-03-31 | -$0.02 | |||
| 2008-12-31 | 2008-12-31 | $0.09 | |||
| 2008-09-30 | 2008-09-30 | $0.04 | |||
| 2008-06-30 | 2008-06-30 | $0.05 | |||
| 2007-12-31 | 2007-12-31 | $0.10 | |||
| 2007-09-30 | 2007-09-30 | $0.04 | |||
| 2007-06-30 | 2007-06-30 | $0.02 | |||
| 2007-03-31 | 2007-03-31 | $0.00 |
Eurofins Scientific SE (ERFSF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | N/A | 91.69 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | 257.96 million |
| Ebit | N/A | N/A | N/A | N/A | 154.39 million |
| Operating Income | N/A | N/A | N/A | N/A | 154.39 million |
| Income Tax Expense | 48.95 million | 48.95 million | 28 million | 28 million | 23.17 million |
| Total Revenue | N/A | N/A | N/A | N/A | 1.2 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 939.6 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -62.7 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 68.52 million |
| Net Income Applicable to Common Shares | 213.8 million | 213.8 million | 47.35 million | 47.35 million | 80.28 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | 187500 | 187500 | 23.61 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -102.65 million | -102.65 million | -158.6 million | -158.6 million | -111.5 million |
| Net Borrowings | -202.05 million | -202.05 million | -2.6 million | -2.6 million | -72.5 million |
| Total Cash Flow from Financial Activities | N/A | N/A | -57.98 million | -57.98 million | -113.12 million |
| Change to Operating Activities | 5.35 million | 5.35 million | 12.94 million | 12.94 million | -41.39 million |
| Change in Cash | N/A | N/A | 5.87 million | 5.87 million | -106.12 million |
| Total Cash from Operating Activities | 222.5 million | 222.5 million | 222.97 million | 222.97 million | 115.98 million |
| Depreciation | N/A | N/A | 87.48 million | 87.48 million | 91.12 million |
| Other Cash Flow from Investing Activities | 600000 | 600000 | 470000 | 470000 | 980000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -20.65 million | -20.65 million | -21.07 million | -21.07 million | -25.53 million |
| Change to Net Income | 69.95 million | 69.95 million | 54.38 million | 54.38 million | 36.82 million |
| Capital Expenditures | N/A | N/A | 119.9 million | 119.9 million | 70.5 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 4.93 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 2.84 billion |
| Other Current Liabilities | 397.6 million | 397.6 million | N/A | N/A | 716.9 million |
| Total Assets | N/A | N/A | N/A | N/A | 7.82 billion |
| Common Stock | 1.9 million | 1.9 million | 1.9 million | 1.9 million | 1.8 million |
| Other Current Assets | N/A | N/A | N/A | N/A | 300000 |
| Retained Earnings | 1.31 billion | 1.31 billion | 821.4 million | 821.4 million | 718.9 million |
| Other Liabilities | 245.5 million | 245.5 million | 261.3 million | 261.3 million | 256.6 million |
| Other Assets | 119.1 million | 119.1 million | 51.8 million | 51.8 million | 43.9 million |
| Cash | N/A | N/A | N/A | N/A | 297 million |
| Total Current Liabilities | 1.7 billion | 1.7 billion | N/A | N/A | 1.58 billion |
| Other Stockholder Equity | 2.38 billion | 2.38 billion | 2.61 billion | 2.61 billion | 2.12 billion |
| Property, Plant & Equipment | 1.57 billion | 1.57 billion | 1.57 billion | 1.57 billion | 1.59 billion |
| Total Current Assets | 2.52 billion | 2.52 billion | N/A | N/A | 1.6 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 54.5 million |
| Net Tangible Assets | -658.9 million | -658.9 million | -1.05 billion | -1.05 billion | -1.69 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 2.68 billion |
| Inventory | 157 million | 157 million | N/A | N/A | 79.3 million |
| Accounts Payable | 278.8 million | 278.8 million | N/A | N/A | 409.8 million |
Eurofins Scientific SE (ERFSF) Chart:
Eurofins Scientific SE (ERFSF) News:
Below you will find a list of latest news for Eurofins Scientific SE (ERFSF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Eurofins Scientific SE (ERFSF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Eurofins Scientific SE (ERFSF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|